SI-BONE is no longer only a sacroiliac-joint specialist. The Santa Clara implant maker is trying to become a broader spinopelvic company built around compromised bone, and the second quarter is the first clean print in which that ambition shows up in both volume and operating leverage. Physician engagement reached a new high, procedure growth ran in the mid-teens, and expense growth lagged revenue by a wide margin. The investment debate is whether that leverage survives a mix shift toward lower-implant trauma and interventional cases, an unresolved Justice Department inquiry, and a reimbursement calendar that still has to convert into hospital demand.
Worldwide sales reached $56 million, a mid-teens advance from the year-ago quarter. United States procedure volume rose almost as fast as domestic revenue, which is the tell that average selling price, the realized price per case, barely moved and may have slipped a touch as mix tilted. Adjusted earnings before interest, taxes, depreciation, and amortization, a non-GAAP profit measure that adds back stock compensation, more than doubled to just under $3 million. Cash and marketable securities still sit near $146 million against modest term debt, so the balance sheet is not the constraint. The constraint is conversion. Centers for Medicare and Medicaid Services finalized a new inpatient payment family for complex fusions that use iFuse Bedrock Granite, effective October first, and a third breakthrough device sits in a June clearance filing with a phased autumn launch.
The counterargument is that management only lifted the low end of the full-year sales range by $1 million, baked in a seasonal third-quarter dip, and still models low-single-digit price erosion. A late-August voluntary recall of a small TORQ lot is financially tiny but is a quality-control signal on a growth product. The open question is whether October reimbursement and the new device actually accelerate the second half, or whether mix and legal overhang keep the print in the mid-teens for longer than the multiple implies.